Abstract 4035: Protein tyrosine kinase 7 (PTK7) biomarker analysis in patients (pts) treated with PF-06647020, a PTK7 antibody-drug conjugate (ADC), in a phase I dose expansion study

Abstract 4035: Protein tyrosine kinase 7 (PTK7) biomarker analysis in patients (pts) treated with PF-06647020, a PTK7 antibody-drug conjugate (ADC), in a phase I dose expansion study

10.1158/1538-7445.am2019-4035 ◽

2019 ◽

Author(s):

Amy Jackson-Fisher ◽

Navi Mehra ◽

Roberto Gianani ◽

Pamela Whalen ◽

Pamela Vizcarra ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Protein Tyrosine Kinase ◽

Antibody Drug Conjugate ◽

Protein Tyrosine ◽

Drug Conjugate ◽

Biomarker Analysis ◽

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3757 ◽

2021 ◽

pp. clincanres.3757.2020

Author(s):

Michael L. Maitland ◽

Jasgit C Sachdev ◽

Manish R Sharma ◽

Victor Moreno ◽

Valentina Boni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Protein Tyrosine Kinase ◽

Human Study ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Protein Tyrosine ◽

Drug Conjugate ◽

PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5565 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5565-5565 ◽

Cited By ~ 10

Author(s):

Jasgit C. Sachdev ◽

Michael L. Maitland ◽

Manish Sharma ◽

Victor Moreno ◽

Valentina Boni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Protein Tyrosine Kinase ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.2574 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 2574-2574 ◽

Cited By ~ 1

Author(s):

Dawei Xuan ◽

Xiaohua (Robert) Xin ◽

Brenda Gibson ◽

Tenshang Joh ◽

Hequn Yin ◽

...

Keyword(s):

Clinical Pharmacology ◽

Tyrosine Kinase ◽

Solid Tumors ◽

Protein Tyrosine Kinase ◽

Adult Patients ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)

Annals of Oncology ◽

10.1093/annonc/mdw435.29 ◽

2016 ◽

Vol 27 ◽

pp. vi570 ◽

Cited By ~ 3

Author(s):

J.C. Sachdev ◽

M. Maitland ◽

M. Sharma ◽

V. Moreno ◽

V. Boni ◽

...

Keyword(s):

Ovarian Cancer ◽

Tyrosine Kinase ◽

Solid Tumors ◽

Protein Tyrosine Kinase ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis

Annals of Translational Medicine ◽

10.21037/atm.2017.09.11 ◽

2017 ◽

Vol 5 (23) ◽

pp. 462-462 ◽

Cited By ~ 7

Author(s):

Masaru Katoh

Keyword(s):

Tyrosine Kinase ◽

Receptor Tyrosine Kinase ◽

Protein Tyrosine Kinase ◽

Whole Body ◽

Growth Factor Signaling ◽

Vascular Endothelial ◽

Antibody Drug Conjugate ◽

Endothelial Growth Factor ◽

Abstract PS10-51: TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancer

10.1158/1538-7445.sabcs20-ps10-51 ◽

2021 ◽

Author(s):

J M Liu ◽

Y M Yin ◽

Hao Wu ◽

W Li ◽

X Huang ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Dose Escalation ◽

Antibody Drug Conjugate ◽

Her2 Positive ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Her2 Positive Breast Cancer ◽

Antibody Drug ◽

Positive Breast Cancer

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70912-7 ◽

2009 ◽

Vol 7 (2) ◽

pp. 266-267 ◽

Cited By ~ 1

Author(s):

H. Burris ◽

S. Vukelja ◽

I. Krop ◽

S. Modi ◽

B. Klencke ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Safety And Efficacy ◽

Drug Conjugate ◽

Clinical significance of expression of protein tyrosine kinase 7 in gastric adenocarcinoma

World Chinese Journal of Digestology ◽

10.11569/wcjd.v23.i20.3213 ◽

2015 ◽

Vol 23 (20) ◽

pp. 3213

Author(s):

Zhi-Qiang Ye

Keyword(s):

Tyrosine Kinase ◽

Clinical Significance ◽

Gastric Adenocarcinoma ◽

Protein Tyrosine Kinase ◽

Protein Tyrosine ◽

Protein Tyrosine Kinase 7

Abstract 4641: Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting antibody drug conjugate

10.1158/1538-7445.am2014-4641 ◽

2014 ◽

Author(s):

Jose F. Ponte ◽

Kelli L. Running ◽

Maurice Kirby ◽

Julie Chan ◽

Jan Pinkas ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Folate Receptor ◽

Phase I Clinical Trial ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽